- Home
- SAVA vs IGMS Comparison
SAVA vs IGMS Comparison
Compare SAVA & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- IGMS
- Stock Information
- Founded
- SAVA 1998
- IGMS 1993
- Country
- SAVA United States
- IGMS United States
- Employees
- SAVA 30
- IGMS N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- SAVA Health Care
- IGMS Health Care
- Exchange
- SAVA Nasdaq
- IGMS Nasdaq
- Market Cap
- SAVA 70.5M
- IGMS 82.1M
- IPO Year
- SAVA N/A
- IGMS 2019
- Fundamental
- Price
- SAVA $1.57
- IGMS $1.32
- Analyst Decision
- SAVA Buy
- IGMS Hold
- Analyst Count
- SAVA 3
- IGMS 8
- Target Price
- SAVA $54.50
- IGMS $6.14
- AVG Volume (30 Days)
- SAVA 1.2M
- IGMS 179.3K
- Earning Date
- SAVA 05-09-2025
- IGMS 05-07-2025
- Dividend Yield
- SAVA N/A
- IGMS N/A
- EPS Growth
- SAVA N/A
- IGMS N/A
- EPS
- SAVA N/A
- IGMS N/A
- Revenue
- SAVA N/A
- IGMS $2,679,000.00
- Revenue This Year
- SAVA N/A
- IGMS $121.76
- Revenue Next Year
- SAVA N/A
- IGMS $46.83
- P/E Ratio
- SAVA N/A
- IGMS N/A
- Revenue Growth
- SAVA N/A
- IGMS 25.77
- 52 Week Low
- SAVA $1.15
- IGMS $0.92
- 52 Week High
- SAVA $42.20
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- SAVA 45.15
- IGMS 51.98
- Support Level
- SAVA $1.37
- IGMS $1.16
- Resistance Level
- SAVA $1.73
- IGMS $1.31
- Average True Range (ATR)
- SAVA 0.13
- IGMS 0.14
- MACD
- SAVA 0.08
- IGMS 0.04
- Stochastic Oscillator
- SAVA 76.72
- IGMS 72.73
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.